Wholesale back-orders take about 10 days to ship depending on what day of the week you order.
This is Sodium Dichloroacetate 99% specification pharmaceutical-grade ‘DCA’.
Contains no organic solvents (Acetone, Toluene, etc.) or Phenols.
For research laboratory studies and veterinary uses only.
Soluble in cold water. Stable under normal temperatures and pressures. Storage: Keep in a cool,dry place. Keep container tightly closed.
–University of Alberta – Sodium Dichloroacetate (DCA) Research Team publishes results of Clinical Trials
–Case Report: Sodium Dichloroacetate (DCA) inhibition of the “Warburg Effect” in a human cancer patient: complete response in non-Hodgkin’s lymphoma after disease progression with rituximab-CHOP.
–PDK1 inhibition is a novel therapeutic target in multiple myeloma.
–Design, synthesis and biological evaluation of N-arylphenyl-2,2-dichloroacetamide analogues as anti-cancer agents.
–Combination of sulindac and Sodium Dichloroacetate (DCA) kills cancer cells via oxidative damage.
–Novel molecular mechanisms of antitumor action of Sodium Dichloroacetate (DCA) against T cell lymphoma: Implication of altered glucose metabolism, pH homeostasis and cell survival regulation.
–Multi-substituted N-phenyl-2, 2-dichloroacetamide analogues as anti-cancer drugs: design, synthesis and biological evaluation.
–Co-treatment of Sodium Dichloroacetate (DCA), omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: in vivo experiments and a case report.
–Influence of Sodium Dichloroacetate (DCA) on lactate production and oxygen consumption in neuroblastoma cells: is DCA a suitable drug for neuroblastoma therapy?
–Sodium Dichloroacetate (DCA) induces different rates of cell death in cancer and noncancer cell lines in vitro.
–Necrosis of cervical carcinoma by Sodium Dichloroacetate (DCA) released from electrospun polylactide mats.
–Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction.
–The influence of Sodium Dichloroacetate (DCA) on the oxidative processes in sarcoma 37.
–Dichloroacetic acid up-regulates hepatic glutathione synthesis via the induction of glutamate-cysteine ligase.
–Targeting metabolism with arsenic trioxide and Sodium Dichloroacetate (DCA) in breast cancer cells.
–In vitro effects of an in silico-modelled 17β-estradiol derivative in combination with dichloroacetic acid on MCF-7 and MCF-12A cells.
–Susceptibility to breast cancer and three polymorphisms of GSTZ1.
–Sodium Dichloroacetate (DCA) induces apoptosis of epithelial ovarian cancer cells through a mechanism involving modulation of oxidative stress.
–Bicarbonate and Sodium Dichloroacetate (DCA): evaluating pH altering therapies in a mouse model for metastatic breast cancer.
–Sodium Dichloroacetate (DCA) inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells.
–Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of Sodium Dichloroacetate (DCA).
–Use of pure oral Sodium Dichloroacetate (DCA) for palliation of leg pain arising from metastatic poorly differentiated carcinoma: a case report.
–Synergistic antitumor effect of Sodium Dichloroacetate (DCA) in combination with 5-fluorouracil in colorectal cancer.
–Development of a dichloroacetic acid-hemoglobin conjugate as a potential targeted anti-cancer therapeutic.
–In vitro cytotoxicity of novel platinum-based drugs and Sodium Dichloroacetate (DCA) against lung carcinoid cell lines.
–High concentrations of Sodium Dichloroacetate (DCA) have minor effects on the vitality of the mammalian nerve fibers: an ex-vivo electrophysiological study.
–Developing new anti-cancer drugs.
–Metabolic-targeted therapy with Sodium Dichloroacetate (DCA): a novel treatment strategy to improve the outcome of photodynamic therapy.
–Anticancer drugs that target metabolism: Is Sodium Dichloroacetate (DCA) the new paradigm?
–The Sodium Dichloroacetate (DCA) dilemma: environmental hazard versus therapeutic goldmine–both or neither?
–Novel N-phenyl dichloroacetamide derivatives as anticancer reagents: design, synthesis and biological evaluation.
–Severe encephalopathy and polyneuropathy induced by Sodium Dichloroacetate (DCA).
–Sodium Dichloroacetate (DCA) reduces apoptosis in colorectal tumor hypoxia.
–Sodium Dichloroacetate (DCA) selectively targets cells with defects in the mitochondrial ETC.
–Sodium Dichloroacetate (DCA) metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs.
–The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts.
–Sodium Dichloroacetate (DCA) induces apoptosis and cell-cycle arrest in colorectal cancer cells.
–Metabolic modulation of glioblastoma with dichloroacetate.
–Targeting cell metabolism in cancer patients.
–Sodium Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24.
–Oxidative stress therapy for solid tumors – a proposal.
–In vitro effects of pure Sodium Dichloroacetate (DCA) and CO2 on hypoxic HeLa cells.
–Mitaplatin, a potent fusion of cisplatin and the pure orphan drug Sodium Dichloroacetate (DCA).
–Pivotal role of the C-terminal DW-motif in mediating inhibition of pyruvate dehydrogenase kinase 2 by Sodium Dichloroacetate (DCA).
–Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect.
–Reversal of the glycolytic phenotype by Sodium Dichloroacetate (DCA) inhibits metastatic breast cancer cell growth in vitro and in vivo.
–Phenylalanine-induced leucopenia in genetic and dichloroacetic acid generated deficiency of glutathione transferase Zeta.
–Evaluation of dichloroacetic acid for carcinogenicity in genetically modified Tg.AC hemizygous and p53 haploinsufficient mice.
–Theoretical studies of different tautomers of anti cancer drug: Sodium Dichloroacetate (DCA).
–Evaluation of the role of peroxisome proliferator-activated receptor alpha (PPARalpha) in mouse liver tumor induction by trichloroethylene and metabolites.
–Sodium Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer.
–Sodium Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation.
–Sodium Dichloroacetate (DCA) induces apoptosis in endometrial cancer cells.
–Analysis of in vivo mutation data can inform cancer risk assessment.
–Metabolic targeting as an anticancer strategy: dawn of a new era?
–Cancer patients opt for unapproved drug.
–A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.
Toxicity Data[LD50/LC50]: Oral, mouse: LD50 = 4845 mg/kg; Oral, rat: LD50 = 5281 mg/kg.
Pure pH: 8.0
Linear Formula Cl2CHCO2Na
Molecular Weight 150.924
EC Number 218-461-3
US Federal Regulatory Information:
CAS# 2156-56-1 is not listed on the TSCA inventory. It is for research and development use only.
Health & Safety Reporting List:
None of the chemicals are on the Health & Safety Reporting List.
Chemical Test Rules:
None of the chemicals in this product are under a Chemical Test Rule.
None of the chemicals are listed under TSCA Section 12b.
TSCA Significant New Use Rule:
None of the chemicals in this material have a SNUR under TSCA.
CERCLA Hazardous Substances and corresponding RQs:
None of the chemicals in this material have an RQ.
SARA Section 302 Extremely Hazardous Substances:
None of the chemicals in this product have a TPQ.
No chemicals are reportable under Section 313.
Clean Air Act:
This material does not contain any hazardous air pollutants.
This material does not contain any Class 1 Ozone depletors.
This material does not contain any Class 2 Ozone depletors.
Clean Water Act:
None of the chemicals in this product are listed as Hazardous Substances under the CWA.
None of the chemicals in this product are listed as Priority Pollutants under the CWA.
None of the chemicals in this product are listed as Toxic Pollutants under the CWA.
None of the chemicals in this product are considered highly hazardous by OSHA.
CAS# 2156-56-1 is not present on state lists from CA, PA, MN, MA, FL, or NJ.
California Prop 65:
California No Significant Risk Level: None of the chemicals in this product are listed.
“Acetic acid, dichloro-, sodium salt”
Pure “Sodium dichloroacetate”
Acetic acid, dichloro-, sodium salt
Dichloroacetate sodium salt
Dichloroacetic acid sodium salt
Dichloroctan sodny [Czech]
Pure Sodium dichloroacetate
Sodium dichloroacetate (USAN)
Sodium dichloroacetate [USAN]